Targets › TYR1R
1 program from 1 company in 1 trial: 1 Phase 4; Ophthalmology; next expected readout Apr 2027.
Open in Phaseline: the race on TYR1R, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| NYU Langone Health | TRYPTYR (Acoltremon ophthalmic solution 0.003%) TYR1 receptor agonist | TYR1R | Phase 4 | Dry Eye Disease (DED) | Apr 2027 |
Dry Eye Disease (DED) (1)
small molecule (1)
NYU Langone Health (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.